Magainin Pharmaceuticals Inc. said Thursday it has been issuedthree U.S. patents covering the use of its anti-infective peptidesin combination with other known anti-infectives to createproducts with enhanced activities.

Magainin (NASDAQ:MAGN) owns two of the patents. No.5,208,220 covers combination products that include certainantibiotics (for broad-spectrum antibacterial activity) and No.5,221,664 covers products that include certain cations,especially silver (for treating or preventing eye infections). Thethird patent, No. 5,217,956, to which Magainin has an exclusiveworldwide license, includes products containing certain anions,notably fluoride, and could find potential uses as oral health-care products, the Plymouth Meeting, Pa., company said.

(c) 1997 American Health Consultants. All rights reserved.